Lonza completes $4.5 billion specialty ingredients divestment

This post was originally published on this site

The deal, announced in February, came as the Swiss contract drug manager pledged to focus on its faster-growing drugs and biotech unit.

“As the divestment of the Specialty Ingredients business completes, at Lonza we have an opportunity to consolidate our identity and redouble our focus on long-term growth,” Chairman Albert Baehny said in a statement on Friday.

($1 = 0.9262 Swiss francs)